Macrogenics (MGNX) Common Equity (2012 - 2026)
Macrogenics (MGNX) posted quarterly Common Equity of $21.2 million for Q1 2026, down 73.21% year-over-year from $79.1 million in Q1 2025, and down 61.87% quarter-over-quarter from $55.6 million in Q4 2025.
Macrogenics (MGNX) Common Equity (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Common Equity for 15 consecutive years, with $21.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 73.21% year-over-year to $21.2 million; the TTM figure through Mar 2026 stood at $21.2 million (down 73.21% YoY), while the FY2025 annual figure was $55.6 million, down 52.1% from the prior year.
- Common Equity eased to $21.2 million in Q1 2026 per MGNX's latest filing, from $55.6 million in the prior quarter.
- Across five years, Common Equity topped out at $194.0 million in Q3 2023 and bottomed at $21.2 million in Q1 2026.
- Historically, Common Equity has averaged $110.7 million across 5 years, with a median of $116.1 million in 2024.
- Annual changes were most pronounced in 2023 — Common Equity jumped 57.76% — and 2026, when it tumbled 73.21%.
- Macrogenics' Common Equity stood at $142.0 million in 2022, then rose by 7.46% to $152.6 million in 2023, then dropped by 23.95% to $116.1 million in 2024, then tumbled by 52.1% to $55.6 million in 2025, then tumbled by 61.87% to $21.2 million in 2026.
- Business Quant data shows MGNX's Common Equity at $21.2 million in Q1 2026, $55.6 million in Q4 2025, and $67.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 21.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.20 Mn |
| Dec 31, 2025 | 55.59 Mn |
| Sep 30, 2025 | 67.00 Mn |
| Jun 30, 2025 | 46.62 Mn |
| Mar 31, 2025 | 79.12 Mn |
| Dec 31, 2024 | 116.06 Mn |
| Sep 30, 2024 | 120.07 Mn |
| Jun 30, 2024 | 57.82 Mn |
| Mar 31, 2024 | 106.15 Mn |
| Dec 31, 2023 | 152.61 Mn |
| Sep 30, 2023 | 193.98 Mn |
| Jun 30, 2023 | 171.54 Mn |
| Mar 31, 2023 | 109.27 Mn |
| Dec 31, 2022 | 142.01 Mn |
| Sep 30, 2022 | 122.96 Mn |
| Jun 30, 2022 | 142.48 Mn |
| Mar 31, 2022 | 178.21 Mn |
| Dec 31, 2021 | 239.62 Mn |
| Sep 30, 2021 | 291.44 Mn |
| Jun 30, 2021 | 319.05 Mn |